文献速递神经肿瘤

18F-FET-PET作为非对比增强胶质瘤化疗后治疗反应的生物标志物

18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy.
PubMed 文献 · J Neurooncol · 2018-06-08

研究纳入61例钆阴性WHO II或III级胶质瘤患者,化疗前及6个月后行MRI和18F-FET-PET,采用BTV和TBRmax分类方案评估反应,结果显示18F-FET-PET反应组TTF最长(78.5 vs 24.6 vs 24.1个月,p=0.001),T2体积评估与结局无关。

要点

  • 18F-FET-PET反应组TTF为78.5个月,稳定组24.6个月,进展组24.1个月(p=0.001)。
  • 18F-FET-PET反应组与稳定组、进展组间PCS差异有统计学意义(p<0.001)。
  • 基于T2体积的评估与结局无关。

核心结论

  • 18F-FET-PET是钆阴性胶质瘤化疗早期反应评估的有前景的生物标志物。
  • 它可能有助于及时调整可能无效的治疗方案,并克服传统结构影像的局限性。

研究设计与样本

  • 纳入61例钆阴性WHO II或III级胶质瘤患者,接受烷化剂(替莫唑胺或CCNU/丙卡巴肼)化疗。
  • 所有患者化疗前及6个月后行MRI和18F-FET-PET,计算T2体积、基于18F-FET-PET的生物肿瘤体积(BTV)和最大肿瘤-脑比值(TBRmax),并进行动态PET时间-活性曲线(TAC)分析。
  • MRI反应评估采用低级别胶质瘤RANO标准;18F-FET-PET采用分类方案:BTV下降≥25%和/或TBRmax下降≥10%为反应性疾病(RD),BTV增加≥25%和/或TBRmax增加>10%为进展性疾病(PD),BTV变化±25%和TBRmax变化±10%为稳定性疾病(SD)。
  • 采用Kaplan-Meier法计算化疗后生存期(PCS)和治疗失败时间(TTF)。

主要发现

  • 18F-FET-PET反应组TTF最长(78.5 vs 24.6 vs 24.1个月,p=0.001),稳定组与进展组间无显著差异。
  • PCS呈现类似模式(p<0.001)。
  • 基于T2体积的评估与结局无关。

关键数值与推荐

  • 18F-FET-PET反应分类:BTV下降≥25%和/或TBRmax下降≥10%为反应性疾病(RD)。
  • BTV增加≥25%和/或TBRmax增加>10%为进展性疾病(PD)。
  • BTV变化±25%和TBRmax变化±10%为稳定性疾病(SD)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monitoring treatment response after chemotherapy of gadolinium-(Gd)-negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that 18F-FET-PET can be used as a biomarker for response assessment in Gd-negative gliomas undergoing chemotherapy. METHODS: Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and 18F-FET-PET before chemotherapy and 6 months later. We calculated T2-volume, 18F-FET-PET based biological tumour volume (BTV) and maximal tumour-to-brain ratio (TBRmax). Moreover, dynamic PET acquisition was performed using time-activity-curves (TACs) analysis. For MRI-based response assessment, RANO criteria for low-grade glioma were used. For 18F-FET-PET, following classification scheme was tested: responsive disease (RD) when a decrease in either BTV ≥ 25% and/or TBRmax ≥ 10% occurred, an increase in BTV ≥ 25% and/or TBRmax increase > 10% characterized progressive disease (PD), minor changes ± 25% for BTV and ± 10% for TBRmax were regarded as stable disease (SD). Post-chemotherapy survival (PCS) and time-to-treatment failure (TTF) were calculated using the Kaplan-Meier method. RESULTS: 18F-FET-PET based response has shown patients with RD to have the longest TTF time (78.5 vs 24.6 vs 24.1 months, p = 0.001), while there was no significant difference between patients with a SD and PD. A comparable pattern was observed for PCS (p < 0.001). T2-volume based assessment was not associated with outcome. CONCLUSION: 18F-FET-PET is a promising biomarker for early response assessment in Gd-negative gliomas undergoing chemotherapy. It might be helpful for a timely adjustment of potentially ineffective treatment concepts and overcomes limitations of conventional structural imaging.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Suchorska B, Unterrainer M, Biczok A, et al. 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. J Neurooncol. 2018. PMID: 29948765. doi:10.1007/s11060-018-2919-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。